Notably, several hyper- and hypomethylated probes were associated with poor survival outcomes, suggesting that epigenetic dysregulation of CBX1 may contribute to tumor progression and serve as a prognostic indicator in LIHC. This evidence concerns the gene CBX1 and neoplasm.